NG MM CAR T
Alternative Names: NG-MM CAR T-bluebird bio; NG-MM-CAR TLatest Information Update: 18 Aug 2021
At a glance
- Originator bluebird bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Aug 2021 NG MM CAR T is available for licensing as of 04 Aug 2021. https://www.bluebirdbio.com/about-us/collaborations
- 04 Aug 2021 Preclinical trials in Cancer in USA (Parenteral) (bluebird bio pipeline, August 2021)